Citations

Clear

3942 citation(s) found for "To, Van".

Anterior nuclear deep brain stimulation guided by concordant hippocampal recording
Klassen, Bryan T. , Lee, Kendall H. , Shin, Cheolsu, Zhao, Cong Zhi, Goerss, Steven J., Kall, Bruce A., Stead, Matt, Gompel, Jamie J. Van , Worrell, Gregory A. , Brown, Desmond , Goerss, S

Mayo Clinic

Neurosurgical Focus | June 1, 2015 | Volume: 38 | Issue: 6 | Pages: E9

10.3171/2015.3.focus1541 | PMID 26030709 Get It

OBJECT Anterior nuclear (AN) stimulation has been reported to reduce the frequency of seizures, in some cases dramatically; however, it has not been approved by the US Food and Drug Administration. The anterior nucleus is difficult to target because of its sequestered location, partially surrounded by the ventricle. It has traditionally been targeted by using transventricular or lateral transcortical routes. Here, the authors report a novel approach to targeting the anterior nucleus and neurophysiologically confirming effective stimulation of the target, namely evoked potentials in the hippocampus. METHODS Bilateral AN 3389 electrodes were placed in a novel trajectory followed by bilateral hippocampal 3391 electrodes from a posterior trajectory. Each patient was implanted bilaterally with a Medtronic Activa PC+S device under an investigational device exemption approval. Placement was confirmed with CT. AN stimulation-induced hippocampal evoked potentials were measured to functionally confirm placement in the anterior nucleus. RESULTS Two patients had implantations by way of a novel AN trajectory with concomitant hippocampal electrodes. There were no lead misplacements. Postoperative stimulation of the anterior nucleus with a PC+S device elicited evoked potentials in the hippocampus. Thus far, both patients have reported a > 50% improvement in seizure frequency. CONCLUSIONS Placing AN electrodes posteriorly may provide a safer trajectory than that used for traditionally placed AN electrodes. In addition, with a novel battery that is capable of electroencephalographic recording, evoked potentials can be used to functionally assess the Papez circuit. This treatment paradigm may offer increased AN stimulation efficacy for medically intractable epilepsy by assessing functional placement more effectively and thus far has proven safe.
Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas
Braggio, Esteban , Wier, Scott Van, Ojha, Juhi, McPhail, Ellen D. , Asmann, Yan W. , Egan, Jan B. , Ayres-Silva, Jackline de Paula , Schiff, David , Lopes, M. Beatriz S. , Decker, Paul A. , Valdez, Riccardo, Tibes, Raoul , Eckloff, Bruce W., Stewart, A. Keith, Van Wier, Scott, McPhail, Ellen, Egan, Jan, Eckloff, Bruce, O'Neill, Brian Patrick, McPhail, Ellen Darcy , Decker, Paul A. , Witzig, Thomas E. , Fonseca, Rafaël , O’Neill, Brian Patrick , Braggio, Esteban

Mayo Clinic

Clinical Cancer Research | May 19, 2015 | Volume: 21 | Issue: 17 | Pages: 3986-3994

10.1158/1078-0432.ccr-14-2116 | PMID 25991819 Get It

Abstract Purpose: Primary central nervous system lymphoma (PCNSL) is an aggressive non-Hodgkin lymphoma confined to the central nervous system. Whether there is a PCNSL-specific genomic signature and, if so, how it differs from systemic diffuse large B-cell lymphoma (DLBCL) is uncertain. Experimental Design: We performed a comprehensive genomic study of tumor samples from 19 immunocompetent PCNSL patients. Testing comprised array-comparative genomic hybridization and whole exome sequencing. Results: Biallelic inactivation of TOX and PRKCD was recurrently found in PCNSL but not in systemic DLBCL, suggesting a specific role in PCNSL pathogenesis. In addition, we found a high prevalence of MYD88 mutations (79%) and CDKN2A biallelic loss (60%). Several genes recurrently affected in PCNSL were common with systemic DLBCL, including loss of TNFAIP3, PRDM1, GNA13, TMEM30A, TBL1XR1, B2M, CD58, activating mutations of CD79B, CARD11, and translocations IgH-BCL6. Overall, B-cell receptor/Toll-like receptor/NF-κB pathways were altered in >90% of PNCSL, highlighting its value for targeted therapeutic approaches. Furthermore, integrated analysis showed enrichment of pathways associated with immune response, proliferation, apoptosis, and lymphocyte differentiation. Conclusions: In summary, genome-wide analysis uncovered novel recurrent alterations, including TOX and PRKCD, helping to differentiate PCNSL from systemic DLBCL and related lymphomas. Clin Cancer Res; 21(17); 3986–94. ©2015 AACR.
Lateralization of mesial temporal lobe epilepsy with chronic ambulatory electrocorticography
King‐Stephens, David , Mirro, Emily A. , Weber, Peter, Laxer, Kenneth D. , Ness, Paul C. Van, Salanova, Vicenta , Spencer, David , Heck, Christianne, Jobst, Barbara C. , Shields, Donald C. , Bergey, Gregory K. , Eisenschenk, Stephan, Rossi, Marvin A. , Sperling, Michael R. , Nair, Dileep , Gwinn, Ryder P. , Park, Yong D., Rutecki, Paul , Fountain, Nathan B. , Wharen, Robert E. , Miller, Ian , Barkley, Gregory L., Geller, Eric B., Berg, Michel J., Sadler, Toni, Sun, Felice T., Morrell, Martha J. , Cole, Andrew J , Goldman, Alica M. , Worrell, Gregory A. , Gross, Robert E. , Cole, Andrew J. , Hirsch, Lawrence J. , Edwards, Jonathan C. W. , Sperling, Michael R , Fountain, Nathan , Jobst, Barbara , Nair, Dileep R , Morrell, Martha J

Mayo Clinic

Epilepsia | May 19, 2015 | Volume: 56 | Issue: 6 | Pages: 959-967

10.1111/epi.13010 | PMID 25988840 Get It

Summary Objective Patients with suspected mesial temporal lobe ( MTL ) epilepsy typically undergo inpatient video–electroencephalography ( EEG ) monitoring with scalp and/or intracranial electrodes for 1 to 2 weeks to localize and lateralize the seizure focus or foci. Chronic ambulatory electrocorticography ( EC oG) in patients with MTL epilepsy may provide additional information about seizure lateralization. This analysis describes data obtained from chronic ambulatory EC oG in patients with suspected bilateral MTL epilepsy in order to assess the time required to determine the seizure lateralization and whether this information could influence treatment decisions. Methods Ambulatory EC oG was reviewed in patients with suspected bilateral MTL epilepsy who were among a larger cohort with intractable epilepsy participating in a randomized controlled trial of responsive neurostimulation. Subjects were implanted with bilateral MTL leads and a cranially implanted neurostimulator programmed to detect abnormal interictal and ictal EC oG activity. EC oG data stored by the neurostimulator were reviewed to determine the lateralization of electrographic seizures and the interval of time until independent bilateral MTL electrographic seizures were recorded. Results Eighty‐two subjects were implanted with bilateral MTL leads and followed for 4.7 years on average (median 4.9 years). Independent bilateral MTL electrographic seizures were recorded in 84%. The average time to record bilateral electrographic seizures in the ambulatory setting was 41.6 days (median 13 days, range 0–376 days). Sixteen percent had only unilateral electrographic seizures after an average of 4.6 years of recording. Significance About one third of the subjects implanted with bilateral MTL electrodes required >1 month of chronic ambulatory EC oG before the first contralateral MTL electrographic seizure was recorded. Some patients with suspected bilateral MTL seizures had only unilateral electrographic seizures. Chronic ambulatory EC oG in patients with suspected bilateral MTL seizures provides data in a naturalistic setting, may complement data from inpatient video‐ EEG monitoring, and can contribute to treatment decisions.
Quality of factor XI activity testing in North American Specialized Coagulation Laboratories
Zantek, Nicole D. , Hsu, Peihong , Meijer, Piet , Smock, Kristi J. , Plumhoff, Elizabeth, Refaai, Majed A. , Cott, Elizabeth M. Van , Zantek, Nicole D

Mayo Clinic

International Journal of Laboratory Hematology | May 15, 2015 | Volume: 37 | Issue: S1 | Pages: 99-107

10.1111/ijlh.12359 | PMID 25976967 Get It

SummaryIntroductionThe performance of factor XI activity (FXI) by laboratories in the North American Specialized Coagulation Laboratory Association proficiency testing program was analyzed.MethodsOver 10 years (2003–2013), 80 samples were distributed; 33–55 laboratories participated per exercise providing 3833 total responses. Analysis was performed on numeric results and qualitative classification of results.ResultsThe sample FXI levels ranged from 3.8 to 154.0 IU/dL. The overall interlaboratory average coefficient of variation (CV%) was 17.5%; the CV was higher for a sample with low (3.8 IU/dL) FXI. Results were correctly classified as abnormal (100%) for a sample with 3.8 IU/dL FXI and normal/borderline normal (97.7%) for 45 samples with 80 to < 140 IU/dL FXI. The classification was heterogeneous for samples with FXI of 50 to < 80 IU/dL. Six specimens were repeat‐tested from 2007 to 2013. The mean FXI was not significantly different in laboratories using the same method on both exercises, suggesting good intralaboratory precision over time. Univariate analysis of data from 2011 to 2012 did not find a consistent significant difference among the activators, analyzers, calibrators, and FXI‐deficient plasmas.ConclusionLaboratories generally performed well in assessment of FXI based on interlaboratory precision when FXI >30 IU/dL and on classification of samples with very low or normal FXI.
ACR Appropriateness Criteria ® Metastatic Epidural Spinal Cord Compression and Recurrent Spinal Metastasis
Metastases:, Expert Panel on Radiation Oncology–Bone, Lo, Simon S. , Ryu, Samuel , Chang, Eric L. , Galanopoulos, Nicholas, Kim, Edward Y. , Kubicky, Charlotte Dai, Lee, Charles P., Rose, Peter S. , Sahgal, Arjun , Sloan, Andrew E. , Traughber, Bryan , Poznak, Catherine Van , Vassil, Andrew D. , Metastases:, Expert Panel on Radiation Oncology–Bone, Jones, Joshua , Teh, Bin Sing

Mayo Clinic

Journal of Palliative Medicine | May 14, 2015 | Volume: 18 | Issue: 7 | Pages: 573-584

10.1089/jpm.2015.28999.sml | PMID 25974663 Get It

Abstract Metastatic epidural spinal cord compression (MESCC) is an oncologic emergency and if left untreated, permanent paralysis will ensue. The treatment of MESCC is governed by disease, patient, and treatment factors. Patient's preferences and goals of care are to be weighed into the treatment plan. Ideally, a patient with MESCC is evaluated by an interdisciplinary team promptly to determine the urgency of the clinical scenario. Treatment recommendations must take into consideration the risk-benefit profiles of surgical intervention and radiotherapy for the particular individual's circumstance, including neurologic status, performance status, extent of epidural disease, stability of the spine, extra-spinal disease status, and life expectancy. In patients with high spinal instability neoplastic score (SINS) or retropulsion of bone fragments in the spinal canal, surgical intervention should be strongly considered. The rate of development of motor deficits from spinal cord compression may be a prognostic factor for ultimate functional outcome, and should be taken into account when a treatment recommendation is made. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every three years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
Anterior Petrosectomy: Consecutive Series of 46 Patients with Attention to Approach-Related Complications
Alikhani, Puya , Youssef, A. Samy , Loveren, Harry van , Boyev, K. Paul, Agazzi, Sivero, Van Gompel, Jamie J, Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | May 13, 2015 | Volume: 76 | Issue: 05 | Pages: 379-384

10.1055/s-0034-1543971 | PMID 26401480 Get It

Conventional Karyotyping and Fluorescence In Situ Hybridization
He, Rong , Wiktor, Anne E., Hanson, Curtis A. , Ketterling, Rhett P. , Kurtin, Paul J. , Dyke, Daniel L. Van , Litzow, Mark R. , Howard, Matthew H., Reichard, Kaaren K. , Ketterling, Rhett P

Mayo Clinic

American Journal of Clinical Pathology | May 13, 2015 | Volume: 143 | Issue: 6 | Pages: 873-878

10.1309/ajcpp6lvmqg4lnck | PMID 25972330 Get It

Inverting papilloma of the temporal bone: Report of four new cases and systematic review of the literature
Carlson, Matthew L. , Sweeney, Alex D. , Modest, Mara C., Haynes, David S. , Neff, Brian A., Van Gompel, Jamie J, Gompel, Jamie J. Van

Mayo Clinic

The Laryngoscope | May 9, 2015 | Volume: 125 | Issue: 11 | Pages: 2576-2583

10.1002/lary.25359 | PMID 25959041 Get It

Objectives/HypothesisInverting papillomas (IPs) are benign locally invasive tumors that most commonly present within the sinonasal cavity. Temporal bone involvement is exceedingly rare, with fewer than 30 cases reported within the English literature to date.Study DesignCase series and systematic review of the literature.MethodsFour consecutive subjects with temporal bone inverting papilloma (TBIP) were treated, and an additional 28 previously published cases were identified in the literature. Main outcome measures were disease presentation, diagnostic evaluation, management strategy, and outcome.ResultsA total of 32 cases were analyzed. The median age at diagnosis was 54 years (mean 54.1; range 19–81 years). Nineteen (59%) patients had synchronous or metachronous sinonasal IP, whereas 13 (41%) had isolated temporal bone disease without sinus involvement. Over half of the patients undergoing microsurgical resection experienced at least one recurrence. Compared to patients with a history of sinus IP, subjects with primary TBIP were younger at time of presentation (44 vs. 58 years; P = 0.012); were more commonly female (62% vs. 32%; P = 0.15); and were less likely to have intracranial spread (8% vs. 26%; P = 0.36), cranial neuropathy (8% vs. 26%; P = 0.36), human papillomavirus positivity (11% vs. 57%; P = 0.11), or associated carcinoma (0% vs. 47%; P = 0.004).ConclusionsInverting papilloma of the lateral skull base is rare and can pose a significant therapeutic challenge. Primary lesions of the temporal bone appear to follow a less aggressive clinical course when compared to those arising in association with sinonasal disease. Gross total resection is the preferred method of treatment, when feasible, given the high rate of recurrence with subtotal resection and risk of associated malignancy.Level of Evidence4. Laryngoscope, 125:2576–2583, 2015
Administration of Spores of Nontoxigenic Clostridium difficile Strain M3 for Prevention of Recurrent C difficile Infection
Gerding, Dale N. , Lee, Christine U. , Cohen, Stuart H. , Murthy, Uma K., Poirier, André, Schooneveld, Trevor Van , Pardi, Darrell S. , Ramos, António , Barron, Michelle , Chen, Hongzi, Villano, Stephen, Meyer, Thomas S.

Mayo Clinic

JAMA | May 5, 2015 | Volume: 313 | Issue: 17 | Pages: 1719

10.1001/jama.2015.3725 | PMID 25942722 Get It